S 5123 117th Congress Senate Crime and Law Enforcement

Breakthrough Therapies Act

Introduced: November 17, 2022 Introduced by: Booker, Cory A. Democratic · New Jersey See on congress.gov

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Nov 17, 2022

Read twice and referred to the Committee on the Judiciary.

Nov 17, 2022

Introduced in Senate

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

Plain-English summary Congressional Research Service

Breakthrough Therapies Act

This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. It also provides for expedited controlled substance registrations through the Drug Enforcement Administration for researchers whose work involves investigational drugs.

What's happening now November 17, 2022

Read twice and referred to the Committee on the Judiciary.

Bill text 1 version

Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Judiciary Committee
Senate

Cosponsors 1

Paul, Rand

Kentucky · Nov 17, 2022

Cite this page click to expand

APA

U.S. Congress. (2026). S. 5123: Breakthrough Therapies Act. 117th Congress. Open America. https://openamerica.io/bill/117-S-5123/

MLA

"S. 5123: Breakthrough Therapies Act." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-S-5123/.

Bluebook (legal)

S. 5123, 117th Cong. (2026), https://openamerica.io/bill/117-S-5123/.

Markdown link

[S. 5123: Breakthrough Therapies Act](https://openamerica.io/bill/117-S-5123/)